A new analysis in the British Journal of Cancer links overall survival to the timing of immune checkpoint inhibitor dosing in advanced cancers. Rather than focusing only on whether immunotherapy works, the cohort study evaluates when treatment is administered as a potential driver of outcomes. The findings shift attention toward regimen logistics and patient selection in real-world sequencing, where delays, scheduling, and exposure windows can vary. For oncology teams, it underscores how operational details may translate into measurable survival differences.